Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Retained Earnings for 6 consecutive years, with -$4189.0 as the latest value for Q3 2025.

  • Quarterly Retained Earnings fell 338.83% to -$4189.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$4189.0 through Sep 2025, down 338.83% year-over-year, with the annual reading at -$37248.0 for FY2024, 99.94% up from the prior year.
  • Retained Earnings for Q3 2025 was -$4189.0 at Inhibikase Therapeutics, down from -$2944.0 in the prior quarter.
  • The five-year high for Retained Earnings was $1754.0 in Q3 2024, with the low at -$108.1 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$36.6 million, with a median of -$34.5 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 100.0% in 2024, while the deepest fall reached 4463725.44% in 2024.
  • Over 5 years, Retained Earnings stood at -$29.8 million in 2021, then tumbled by 60.55% to -$47.9 million in 2022, then crashed by 39.75% to -$66.9 million in 2023, then surged by 99.94% to -$37248.0 in 2024, then surged by 88.75% to -$4189.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$4189.0, -$2944.0, and -$108.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.